The effectiveness of miconazole was evaluated in 37 documented fimgal infections, 32 of which were major infections. All patients were receiving therapy for advanced malignancy, with 28 patients having acute leukemia. The overall cure rate was 41% and it was also 41% for major fungal infections. Nine of 22 patients with Candida albicans infections were cured, and 3 of 11 patients with Candida tropicalis infections were cured. A total of 183 patients who received miconazole for presumed or documented fungal infection were evaluated for toxicity. Nausea and vomiting and central nervous system toxicity were the most common side effects, occurring in 25 and 16% of the patients, respectively. Overall, the drug was tolerated well, with only four patients requiring the drug to be permanently discontinued because of toxicity.
Due to the improvements in the treatment of malignancy, an increasing number of patients with cancer are achieving remissions and, ultimately, extended survival and cure (15) . Unfortunately both the therapeutic regimens and the malignant process may often severely compromise host defense mechanisms. The need for improved supportive care in the compromised host is well recognized. The opportunistic infections, including fungal infections, which occur in these patients, constitute a major problem. Often these patients fail to respond to appropriate antimicrobial therapy. This is especially true for patients with hematological malignancies who develop major fungal infections (2) .
One of the frustrating problems in the management of fungal infections in cancer patients is the difficulty in establishing a diagnosis early in the course of the infection. The infecting organism is cultured from blood specimens from only 25% of patients with disseminated infections (2) , and available diagnostic serological methods have lacked consistent reliability (9) . This has resulted in administering of antifungal treatment on presumptive clinical evidence.
The treatment of fungal infections in cancer patients is often unsuccessful and associated with excessive toxicity. Amphotericin B, the most widely used systemic antifungal agent, is not uniformly effective in the compromised host. In neutropenic patients with disseminated Candida infections there is, at most, a 25% response to amphotericin B, with response seldomly observed unless there is recovery from myelosuppression (2) . Higher responses to amphotericin B have been reported in patients who develop fungal infection as a postoperative complication (5) . The use of amphotericin B is frequently limited by its toxicity. In patients receiving chronic drug administration, azotemia has been reported in 80%, hypokalemia in 20%, and anemia in 80% (8) . The use of other nephrotoxic agents for treatment of preceding or concomitant bacterial infection may further potentiate the nephrotoxicity of amphotericin B. Miconazole, a new imidazole antifungal agent, has a broad spectrum of activity in vitro against various fungal organisms (10, 14) . It has been used successfully with minimal toxicity in the therapy of disseminated coccidioidomycosis (11, 12) , candidiasis (6) and Petriellidium boydii infections (7) . In addition, miconazole has been used successfully in treatment of fungal meningitis (4, 13 Major infections were considered to be present when fungi were cultured from an organ such as the liver, lung, kidney, or spleen, from the central nervous system, or from the blood or multiple skin sites, indicating disseminated disease (3). Esophagitis and joint infections were considered to be minor infections. Cure was defined as complete microbiological, histological, and clinical resolution of the infection.
Miconazole was kindly provided for this study by Janssen R & D, Inc., New Brunswick, N.J. The drug was administered in doses ranging from 600 to 1,200 mg every 8 h. Each dose was dissolved in 200 ml of 5% dextrose solution and infused intravenously over 1 to 2 h. The infusion time was increased in some patients who developed toxicity during drug administration. Toxicity was evaluated in all 183 patients who received the drug. Complete blood counts, SMA 12, and urinalysis were performed in all patients before the administration of the first dose of miconazole, during treatment, and on the last day of treatment. Multiple attempts to further document the presence of fungal infection were made during treatment in all patients.
RESULTS
Response. Table 2 summarizes all cases which responded to treatment with miconazole. C|1 03 LO k~~----patients whose neutrophil count was <1,000/ mm3. Table 5 shows response of major infections related to the patients' initial neutrophil counts. There was a 67% cure rate when the neutrophil count was >1,000/mm3, whereas there was only a 38% cure rate when the neutrophil count was <100/mm3 on the first day of therapy. Patients whose neutrophils increased during therapy had a higher response rate than patients whose neutrophils remained unchanged during therapy (47 versus 33%). Only 2 of 7 patients whose neutrophil count remained <100/mm3 were cured of their infection.
Toxicity. Table 6 Fifteen of 37 patients who received at least 5 days of miconazole therapy were cured of their infection. Thirteen of the 32 patients with major fungal infections were cured. As expected, C. albicans was the most frequently isolated fungus and responded to miconazole more frequently than C. tropicalis. T. glabrata is being recognized increasingly as an etiological agent in opportunistic infections (1) . Both patients with Torulopsis infections were cured with miconazole.
The most significant toxicity from miconazole was nausea or vomiting or both which occurred in 25% of the patients. This side effect frequently interfered with nutrition and occasionally was felt to potentiate the gastrointestinal side effects of chemotherapeutic agents. When miconazole was used concomitantly with trimethoprim-sulfamethoxazole, potentiation of this toxicity also was observed. The degree of nausea could generally be reduced or alleviated by increasing infusion time of miconazole to 2 h or more.
Central nervous system toxicity was seen in 29 patients, and the drug was discontinued in 3 patients who had grand mal seizures while receiving miconazole. In all three patients, the seizure activity was preceded by several days of progressive fine tremors. Miconazole was discontinued in one other patient who had a sudden respiratory arrest associated with the first dose of miconazole. The patient was easily resuscitated, although the exact mechanism for the arrest was unclear. In general, the drug was well tolerated, and the -side effects were easily controlled.
This study suggests that miconazole is a useful agent for the treatment of Candida spp. and T. glabrata infections in patients with advanced malignancy. Although the cure rate is low, it is comparable to that observed with amphotericin B in these patients and is associated with much less serious toxicity. Aspergillus infections have not responded to the drug clinically. Responses to miconazole were not seen in other fungal infections, although no conclusions can be made regarding these organisms due to the small numbers. Further studies are needed to compare miconazole with amphotericin B in this difficult group of patients. 
